MedTrace Logo

Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers

NCT06831786 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-12-04

Study results available
· View outcomes & findings →

Summary

This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.

Conditions

  • COVID - 19

Interventions

BIOLOGICAL

Bivalent mRNA SARS-CoV-2 vaccine

Administering a booster dose of the bivalent mRNA vaccine BNT162b2

BIOLOGICAL

Quardrivalent influenza vaccine

Administering a VaxigripTetra™

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Sarunyou Chusri, M.D., Ph.D. · Prince of Songkla University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06831786 on ClinicalTrials.gov